Melinta Therapeutics Inc News - MLNT

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019 52 Presentations by Coalition Members During the Annual...

Initial Statement of Beneficial Ownership (3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ...

Melinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and Director

MORRISTOWN, N.J., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (Nasdaq: MLNT), a...

Amended Statement of Beneficial Ownership (sc 13d/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Quarterly Report (10-q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C...

Melinta Therapeutics Names David Gill as Chairman and Announces CEO Succession Plan

MORRISTOWN, N.J., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a...

Melinta Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update

~ Revenue of $16.0 million, Including Net Product Sales of $13.8 million, for the Second Quarter 2019 ~ ~...

Melinta Therapeutics Announces Rescheduling of Second Quarter 2019 Financial Results Reporting

~ Second Quarter 2019 Financial Results to be Reported on Friday, August 9, 2019 ~ ~ Company Cancels...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C...

Melinta Therapeutics Announces Preliminary Second Quarter 2019 Financial Results and Provides Corporate Update

~ Expects to Report Second Quarter 2019 Net Product Sales of Approximately $13.8 Million, Which Represents an...

Amended Statement of Ownership (sc 13g/a)

SCHEDULE 13G Amendment No. 3 MELINTA THERAPEUTICS INC COMMON STOCK Cusip #58549G209 Check the appropriate box to...

Amended Statement of Beneficial Ownership (sc 13d/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Melinta Therapeutics Inc (MLNT)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

MLNT News

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019

Initial Statement of Beneficial Ownership (3)

Current Report Filing (8-k)

Melinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and Director

Amended Statement of Beneficial Ownership (sc 13d/a)

Quarterly Report (10-q)

Current Report Filing (8-k)

Melinta Therapeutics Names David Gill as Chairman and Announces CEO Succession Plan

Melinta Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update

Melinta Therapeutics Announces Rescheduling of Second Quarter 2019 Financial Results Reporting

Current Report Filing (8-k)

Melinta Therapeutics Announces Preliminary Second Quarter 2019 Financial Results and Provides Corporate Update

Amended Statement of Ownership (sc 13g/a)

Amended Statement of Beneficial Ownership (sc 13d/a)

Current Report Filing (8-k)

MLNT Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Melinta Therapeutics Inc (MLNT) News

Melinta Therapeutics Inc (MLNT)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

MLNT News

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019

Initial Statement of Beneficial Ownership (3)

Current Report Filing (8-k)

Melinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and Director

Amended Statement of Beneficial Ownership (sc 13d/a)

Quarterly Report (10-q)

Current Report Filing (8-k)

Melinta Therapeutics Names David Gill as Chairman and Announces CEO Succession Plan

Melinta Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update

Melinta Therapeutics Announces Rescheduling of Second Quarter 2019 Financial Results Reporting

Current Report Filing (8-k)

Melinta Therapeutics Announces Preliminary Second Quarter 2019 Financial Results and Provides Corporate Update

Amended Statement of Ownership (sc 13g/a)

Amended Statement of Beneficial Ownership (sc 13d/a)

Current Report Filing (8-k)

MLNT Discussion

Your Recent History